To further validate the role of BCOR deregulations in RT patients, we analysed metadata from three recent studies [1, 14, 15] comparing longitudinal samples from CLL patients who developed RT. The gene discussed is BCOR; the disease is B-cell chronic lymphocytic leukemia.